Skip to main content

Table 3 Predictors of HBV-DNA viremia among patients with HIV-HBV co-infection: Univariate analyses

From: Predictors of HBeAg status and hepatitis B viraemia in HIV-infected patients with chronic hepatitis B in the HAART era in Brazil

  Plasma HBV
DNA < 60 UI/mL
Plasma HBV
DNA > 60 UI/mL
OR 95% CI p
Sex      0. 79
female 2 (66. 67%) 1(33. 33%) 1. 00   
male 48(59. 26%) 33(40. 74%) 1. 37 0. 11-15. 79  
Age      0. 41
< = 42 22(55%) 18(45%) 1. 00   
> 42 27(62. 79%) 16(37. 21%) 0. 72 0. 30-1. 74  
CD4      0. 47
< 350 cels/μ1 14 (53. 85%) 12(46. 15%) 1. 00   
> 350 cels/μ1 36 (62. 07%) 22 (37. 93%) 0. 71 0. 27-1. 81  
Under HAART*      0. 005
yes 50(63. 29%) 29(36. 71%)    
no zero 05 (100%)    
HBV Genotype      
A 4 (20%) 16 (80%) 0. 36 0-2. 9 0. 63
Non-A 1 (8. 3%) 11 (91. 6%) 1. 00   
Previous exposure to LAM      0. 10
no 2(28. 57%) 5(71. 43%) 1. 00   
yes 48(62. 34%) 29(37. 66%) 0. 24 0. 04-1. 32  
Under TDF      0. 005
no 15(17. 8%) 21(25. 16%) 1. 00   
yes 35(41. 6%) 13(15. 4%) 0. 26 0. 10-0. 66  
Use of TDF > 12 months      0. 047
no 21(25%) 27(32. 1%) 1. 00   
yes 29(34. 5%) 7(8. 2%) 0. 24 0. 059-0. 97  
ALT level      0. 004
Normal 44(53. 6%) 19(23. 1%) 1. 00   
> 1. 5 ULN** 6(7. 3%) 13(15. 7%) 5. 01 1. 65-15. 17  
Compliance with therapy      0. 033
no 01(14. 29%) 06(85. 71%) 10. 5 1. 20-91. 71  
yes 49(63. 64%) 28(36. 36%) 1. 00   
  1. Under HAART*- Previous use of either lamivudine (LAM) or tenofovir (TDF)
  2. ULN**-Upper Limit of Normality